<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03342664</url>
  </required_header>
  <id_info>
    <org_study_id>11899</org_study_id>
    <nct_id>NCT03342664</nct_id>
  </id_info>
  <brief_title>MIND: Artemis in the Removal of Intracerebral Hemorrhage</brief_title>
  <official_title>MIND: A Prospective, Multicenter Study of Artemis a Minimally Invasive Neuro Evacuation Device, in the Removal of Intracerebral Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penumbra Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Penumbra Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this multicenter randomized controlled study is to compare the&#xD;
      safety and efficacy of minimally invasive hematoma evacuation with the Artemis Neuro&#xD;
      Evacuation Device to best medical management for the treatment of intracerebral hemorrhage&#xD;
      (ICH).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to either minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management (MIS group) or best medical management alone (2:1) (MM).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>180 day mRS is blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Global disability (functional outcome) assessed via the ordinal modified Rankin score (mRS)</measure>
    <time_frame>180 days</time_frame>
    <description>(0 no symptoms - 5 severe disability)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of mortality</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional outcomes measured via weighted modified Rankin Score (mRS)</measure>
    <time_frame>180 days</time_frame>
    <description>(0 no symptoms - 5 severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcomes measured via modified Rankin Score (mRS)</measure>
    <time_frame>365 days</time_frame>
    <description>(0 no symptoms - 5 severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed via Stroke Impact Scale</measure>
    <time_frame>180 and 365 days</time_frame>
    <description>Measures mobility and activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed via EQ-5D-5L</measure>
    <time_frame>180 and 365 days</time_frame>
    <description>Self assessment on activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Admission to hospital discharge (up to one year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU</measure>
    <time_frame># of days from admission (up to one year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of procedure</measure>
    <time_frame>Time in minutes at the time of surgery (up to one day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcomes measured via modified Rankin Score (mRS) of ≤ 3</measure>
    <time_frame>180 days</time_frame>
    <description>(0 no symptoms - 5 severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcomes measured via modified Rankin Score (mRS) of ≤ 2</measure>
    <time_frame>180 days</time_frame>
    <description>(0 no symptoms - 5 severe disability)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cerebral Hemorrhage</condition>
  <condition>Brain Hemorrhage</condition>
  <condition>Cerebral Parenchymal Hemorrhage</condition>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Artemis + Medical Management (MIS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best Medical Management Alone (MM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best medical management alone per standard of care at treating institution</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Artemis + Medical Management</intervention_name>
    <description>Subject will receive best MM in addition to the MIS procedure with Artemis.</description>
    <arm_group_label>Artemis + Medical Management (MIS)</arm_group_label>
    <other_name>MIS + MM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Medical Management Alone (MM)</intervention_name>
    <description>Subject will receive best MM for ICH as determined by stroke physician following AHA/ESO guidelines.</description>
    <arm_group_label>Best Medical Management Alone (MM)</arm_group_label>
    <other_name>MM</other_name>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient age ≥ 18 and ≤ 80&#xD;
&#xD;
          2. Supratentorial ICH of volume ≥ 20 and ≤ 80 cc (measured using A x B X C/2 method)&#xD;
&#xD;
          3. Hemostasis as confirmed by no arterial spot sign (may perform additional scan(s) every&#xD;
             6 hours to demonstrate hemostasis)&#xD;
&#xD;
          4. NIHSS ≥ 6&#xD;
&#xD;
          5. GCS ≥ 5 and ≤ 15&#xD;
&#xD;
          6. Historical mRS 0 or 1&#xD;
&#xD;
          7. Symptom onset &lt; 24 hours prior to initial CT/MR&#xD;
&#xD;
          8. MIS must be initiated within 72 hours of ictus/bleed&#xD;
&#xD;
          9. SBP must be &lt; 180 mmHg and controlled at this level for at least 6 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Imaging&#xD;
&#xD;
               1. &quot;Arterial Spot Sign&quot; identified on final CTA indicating expanding hemorrhage&#xD;
&#xD;
               2. Hemorrhagic lesion such as a vascular malformation (cavernous malformation, AVM&#xD;
                  etc.), aneurysm, and/or neoplasm&#xD;
&#xD;
               3. Hemorrhagic conversion of an underlying ischemic stroke&#xD;
&#xD;
               4. Infratentorial hemorrhage&#xD;
&#xD;
               5. Primary thalamic ICH (where the center of the hemorrhage emulates from the&#xD;
                  thalamus)&#xD;
&#xD;
               6. Associated intra-ventricular hemorrhage requiring treatment for IVH-related mass&#xD;
                  effect or shift due to trapped ventricle (EVD for ICP management is allowed)&#xD;
&#xD;
               7. Midbrain extension/involvement&#xD;
&#xD;
               8. Absolute contraindication to CTA, conventional angiography and MRA&#xD;
&#xD;
          2. Coagulation Issues&#xD;
&#xD;
               1. Absolute requirement for long-term anti-coagulation (e.g., mechanical valve&#xD;
                  replacement (bio-prostatic valve is permitted), high risk atrial fibrillation)&#xD;
&#xD;
               2. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency&#xD;
&#xD;
               3. Platelet count &lt; 100 x 10^3 cells/mm3 or known platelet dysfunction&#xD;
&#xD;
               4. INR &gt; 1.4, elevated prothrombin time or activated partial thromboplastin time&#xD;
                  (aPTT), which cannot be corrected or otherwise accounted for (i.e., lupus&#xD;
                  anti-coagulant)&#xD;
&#xD;
               5. Use of direct factor Xa inhibitors (e.g. apixaban, rivaroxaban, fondaparinux)&#xD;
                  within last 48 hours&#xD;
&#xD;
          3. Patient Factors&#xD;
&#xD;
               1. Traumatic ICH&#xD;
&#xD;
               2. High risk atrial fibrillation (e.g., mitral stenosis with atrial fibrillation)&#xD;
                  and/or symptomatic carotid stenosis&#xD;
&#xD;
               3. Requirement for emergent surgical decompression or uncontrolled ICP after EVD&#xD;
&#xD;
               4. Unable to obtain consent per Institution Review Board/Ethics Committee policy&#xD;
&#xD;
               5. Pregnancy or positive pregnancy test (either serum or urine). Women of&#xD;
                  child-bearing potential must have a negative pregnancy test prior to enrollment&#xD;
&#xD;
               6. Severe active infection requiring treatment (e.g. sepsis or purulent wound) at&#xD;
                  the time of enrollment&#xD;
&#xD;
               7. Renal failure indicated by creatinine &gt; 2 mg/dL or undergoing dialysis&#xD;
&#xD;
               8. Any comorbid disease or condition expected to compromise survival or ability to&#xD;
                  complete follow-up assessments through 365 days&#xD;
&#xD;
               9. Based on investigator's judgement, patient is unwilling or unable to comply with&#xD;
                  protocol follow up appointment schedule&#xD;
&#xD;
              10. Active drug or alcohol use or dependence that, in the opinion of the site&#xD;
                  investigator would interfere with adherence to study requirements&#xD;
&#xD;
              11. Currently participating in another interventional (drug, device, etc) clinical&#xD;
                  trial. Patients in observational, natural history, and/or epidemiological studies&#xD;
                  not involving intervention are eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marisol Clemens</last_name>
    <phone>+1 510 995 2494</phone>
    <email>mclemens@penumbrainc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brooke Lawson</last_name>
    <phone>+1 510 995 2183</phone>
    <email>blawson@penumbrainc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey Colby, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikas Rao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish - HCA</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Arias, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Matouk, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christiana Health</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lief Bohman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>George Washington</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitri Sigounas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Babak Jahromi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Fraser, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40292</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dale Ding, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Mississippi</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chad Washington, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farhan Siddiq, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlantic Neuroscience Institute</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Saphier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Ullman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Kellner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Fiorella, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novant Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziad Hage, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yin Hu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Schirmer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MUSC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Methodist University Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Nickele, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Ryan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Levitt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cian O'Kelly, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Vajkoczy, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>November 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICH</keyword>
  <keyword>Stroke</keyword>
  <keyword>Cerebral Hemorrhage</keyword>
  <keyword>Intracranial Hemorrhage</keyword>
  <keyword>Hemorrhage</keyword>
  <keyword>Cerebrovascular Disorders</keyword>
  <keyword>Brain bleed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

